Key result
Common oral antihypertensives in pregnancy did not alter adverse fetal heart rate effects compared to placebo.
Why the study?
Do common oral antihypertensives alter fetal or neonatal heart rate characteristics in pregnant women with hypertension?
Systematic Review (n=1,997)
Do common oral antihypertensives alter fetal or neonatal heart rate characteristics in pregnant women with hypertension?
Available data are insufficient to determine if common oral antihypertensives adversely affect fetal or neonatal heart rate patterns, suggesting observed changes may be due to underlying disease progression.
Answers are grounded in this paper and cite their sources.
Supports safety of oral antihypertensives on fetal heart rate in pregnancy; extends evidence that changes reflect disease rather than treatment.
OBJECTIVE: To examine fetal (FHR) and neonatal heart rate patterns following use of common oral antihypertensives in pregnancy. METHODS: A systematic review of randomized controlled trials (RCTs), observational studies (N >/= 6 women), and animal studies. Data were abstracted (two reviewers) to determine relative risk (RR) (or risk difference (RD) for low event rates) and 95% CI. RESULTS: Eighteen RCTs (1858 women), one controlled observational study (N = 22), and seven case series (N = 117) were reviewed. Most hypertension was pregnancy-induced (N = 14 studies). The FHR was assessed by cardiotocogram (CTG) (N = 17 studies (visual interpretation); 1 study (computerized CTG), or umbilical artery velocimetry (N = 4). Four studies examined neonatal heart rate. In placebo-controlled RCTs (N = 192 women), adverse FHR effects did not differ between groups [9/101 (drugs) vs. 7/91 (placebo); RD 0.02, 95% CI (- 0.06, 0.11); chi2 = 1.02]. In six drug vs. drug RCTs (295 women), adverse FHR effects did not differ between groups [29/144 (methyldopa) vs. 42/151 (other drugs); RR 0.72, 95% CI (0.49, 1.07); chi2 = 0.69]. In one labetalol vs. placebo trial, neonatal bradycardia did not differ between groups [4/70 (labetalol) vs. 4/74 (placebo); OR 1.06, 95% CI (0.26, 4.39)], while in three drug vs. drug RCTs, neonatal bradycardia was not observed (0/24 vs. 0/26). CONCLUSIONS: Available data are inadequate to conclude whether oral methyldopa, labetalol, nifedipine, or hydralazine adversely affect fetal or neonatal heart rate and pattern. Until definitive data are available, FHR changes cannot be reliably attributed to drug effect, but may be due to progression of the underlying maternal or placental disease.
No takes yet. Share an insight, caveat, or question.
Waterman et al. (2004) conducted a systematic review in Hypertension in pregnancy (n=1,997). Oral antihypertensives (methyldopa, labetalol, nifedipine, hydralazine) vs. Placebo or other antihypertensives was evaluated on Adverse fetal heart rate (FHR) effects (placebo-controlled RCTs) (RD 0.02, 95% CI -0.06, 0.11). Common oral antihypertensives in pregnancy did not alter adverse fetal heart rate effects compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: